NCT01653925 2025-11-24
Molecular Mechanisms of Dutasteride and Dietary Interventions to Prevent Prostate Cancer and Reduce Its Progression
CHU de Quebec-Universite Laval
Phase NA Active not recruiting
Clinical Trials
27 trialsNCT01342367 2025-06-10
Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer
University of Chicago
Phase NA Active not recruiting
NCT00668642 2023-08-22
Effect of Dutasteride on Androgen-Response Gene Expression in Patients With Advanced Prostate Cancer
Endeavor Health
Phase 2 Completed
NCT06001619 2023-08-21
PROMED
Turku University Hospital
Phase 4 Recruiting
NCT00866554 2023-06-02
Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy
CHU de Quebec-Universite Laval
Phase 2 Completed
NCT05705700 2023-02-27
Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP)
Masonic Cancer Center, University of Minnesota
Phase 2 Withdrawn
NCT01594502 2020-10-12
Validation of Digital Morphometry for Cancer Risk in Benign Prostate Biopsies
University of Illinois at Chicago
Completed
NCT01547299 2018-10-23
Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer
Pfizer
Phase 2 Completed
NCT00298155 2018-08-09
TAPS
University of Washington
Phase 2 Completed
NCT01393730 2018-03-15
Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00780754 2018-03-06
Prevention of Prostate Cancer With Dutasteride in Case of High Grade PIN Neoplasia
Kaunas University of Medicine
Phase 3 Completed
NCT00883909 2017-07-11
ARI103094-Follow-Up Study for REDUCE Study Subjects
GlaxoSmithKline
Completed
NCT01337258 2017-05-30
Economic Analyses of the REDUCE Trial
GlaxoSmithKline
Completed
NCT00470834 2017-02-27
Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy
GlaxoSmithKline
Phase 4 Completed
NCT00375765 2017-01-19
Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
GlaxoSmithKline
Phase 4 Completed
NCT00553878 2016-10-14
AVIAS
Canadian Urology Research Consortium
Phase 2/3 Completed
NCT00056407 2016-09-23
REDUCE
GlaxoSmithKline
Phase 3 Completed
NCT00985738 2016-05-17
Role of Dutasteride in Patients Undergoing 3D Mapping Biopsy in Early Stage Prostate Cancer
University of Colorado, Denver
Phase 2 Terminated
NCT00673127 2015-04-22
KHAD
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02159690 2015-01-26
A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy
Johns Hopkins University
Phase 2 Withdrawn
NCT00805701 2014-05-14
Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
Bay State Clinical Trials, Inc.
Phase 4 Completed
NCT00706966 2014-01-17
MRI and Magnetic Resonance Spectroscopy Imaging in Patients Receiving Dutasteride for Benign Prostatic Hypertrophy and Low-Risk Prostate Cancer
University of California, San Francisco
Phase NA Completed
NCT00398281 2014-01-10
Dutasteride Followed By Ultrasound-Guided Biopsy in Finding Prostate Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT01193855 2013-08-26
Dutasteride in Treating Patients With Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00403000 2013-05-01
Dutasteride in Treating Patients With Recurrent Prostate Cancer That Did Not Respond to Androgen-Deprivation Therapy
Roswell Park Cancer Institute
Phase 2 Completed
NCT00558363 2012-03-21
ARTS
GlaxoSmithKline
Phase 2 Completed
NCT01525914 2012-02-03
Response of Patients on Surveillance for Prostate Cancer to Dutasteride
Sunnybrook Health Sciences Centre
Completed